# Carfilzomib Plus Belinostat in Relapsed/Refractory NHL

> **NCT02142530** · PHASE1 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 19 (actual)

## Conditions studied

- Non-Hodgkin Lymphoma
- Diffuse Large B-cell Lymphoma
- Mantle Cell Lymphoma
- Follicular Lymphoma
- Peripheral T-cell Lymphoma

## Interventions

- **DRUG:** Carfilzomib
- **DRUG:** Belinostat

## Key facts

- **NCT ID:** NCT02142530
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2017-03
- **Final completion:** 2018-01
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2018-01-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02142530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02142530, "Carfilzomib Plus Belinostat in Relapsed/Refractory NHL". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02142530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*